Boehringer Ingelheim Launches LENZELTA Vaccine
Analysis based on 6 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026
The launch of LENZELTA by Boehringer Ingelheim is expected to positively impact the animal health market, particularly within the dairy farming sector in the European Union, by offering a new solution to a significant economic burden. This innovation could lead to increased revenue for Boehringer Ingelheim and improved productivity for dairy farms.
Boehringer Ingelheim has launched LENZELTA, a new vaccine designed to significantly reduce the incidence and severity of clinical mastitis in dairy cows and heifers. This vaccine targets key mastitis pathogens, S. aureus and E. coli, offering early and long-lasting protection. LENZELTA will be available in several countries within the European Union starting April 2026. Dr. Gerald Behrens, Head of Ruminants at Boehringer Ingelheim, emphasized the vaccine's role in addressing the substantial economic burden mastitis places on dairy farms worldwide, providing veterinarians and farmers with a powerful new tool for proactive herd health management.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard